Our scientists use Quality-By-Design (QbD) tools at all stages of formulation development. Design of experiments (DOE) along with risk assessment strategies allows us to design our experimental plan. Our development approach allows us to meet our delivery timelines and helps us in providing with cost-effective drug delivery solutions.
- Tablets: Immediate-release, Sustained-release, Delayed-release, Film-coated, Layered tablet, multi-unit particulate system (MUPS), taste masking technologies.
- Capsules: Powder, Granules and Pellets
- Parenteral: Solutions, Suspensions, Emulsions, Infusions
- Ophthalmic: Solutions, Suspensions, Emulsions
- Pellets: Into tablets or Capsule filled
- Powders: Powder in a bottle, Powder for Injection, powder for oral suspension
- Liquids: Solutions, Suspensions, Emulsions
- Semi-solids: Creams, Ointments, Gels, Lotions
- Direct compression
- Dry Granulation
- High shear
- granulation
- Fluid bed granulation
- Roller compaction
- Wurster coating
- Micronization
- Encapsulation
- Injectable
- yophilisation
- Generic product development
- First to file Generic products
- Complex Generics
- Niche Generics
- NCE formulation
- 505(b)2 submissions
- Direct Tablet Compression
- Fluid Bed Processing (Granulation, Drying, Coating)
- High Shear Granulation
- Dry Granulation (Roller Compaction, Slugging)
- Automated Capsule Filling (Powder, Granules, Pellets)
- Low Humidity/Moisture Requirements
- Taste-Masking
- High Potency Compound Handling